Evolus Q2 2023 Earnings Report $11.62 -0.11 (-0.94%) (As of 10:27 AM ET) Earnings HistoryForecast Evolus EPS ResultsActual EPS-$0.28Consensus EPS -$0.26Beat/MissMissed by -$0.02One Year Ago EPSN/AEvolus Revenue ResultsActual Revenue$49.35 millionExpected Revenue$46.12 millionBeat/MissBeat by +$3.23 millionYoY Revenue GrowthN/AEvolus Announcement DetailsQuarterQ2 2023Date8/2/2023TimeN/AConference Call ResourcesSlide DeckPress ReleaseEOLS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Evolus Earnings HeadlinesEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 13, 2024 | businesswire.comEvolus’ Resilience and Growth Potential Amid Market Challenges: A Buy Recommendation by Uy EarNovember 20, 2024 | markets.businessinsider.comMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 18, 2024 | Brownstone Research (Ad)Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their ForecastsNovember 9, 2024 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comEvolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market ChallengesNovember 7, 2024 | finance.yahoo.comSee More Evolus Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evolus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evolus and other key companies, straight to your email. Email Address About EvolusEvolus (NASDAQ:EOLS), a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.View Evolus ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
